DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lumbar disc degeneration — screening already-approved drugs against its 21-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLumbar disc degeneration maps to a 21-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lumbar disc degeneration is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
matrix metallopeptidase 9 (MMP9) — MMP9 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-azanyl-4-fluoranyl-5,7,8,9-tetrahydropyrido[4,3-c]azepin-6-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8K5Y · 1.52 Å · ligand (3-azanyl-4-fluoranyl-5,7,8,9-tetrahydropyrido[4,3-c]azepin-6-yl)-[6-(2-oxidanylpropan-2-yl)-1H-indol-2-yl]methanone (VP6). Experimental structure, not a prediction.
What the evidence adds up to
A 2012 review states that treatment options for lumbar degenerative disc disease remain suboptimal and that the development and outcomes of novel options are currently unpredictable. The same review notes that traditional treatment aims at symptomatic relief by limiting motion, while novel strategies involving stem cells, growth factors, and gene therapy have the theoretical potential to prevent, slow, or reverse disc degeneration. A 2015 review repeats this characterisation, adding that direct injection of active substance is among the novel approaches attracting attention, but again offers no clinical results.
A 2013 cross-sectional study of 163 patients with lumbar disc degeneration (mean age 43.92 years) found disc degeneration most commonly at L4/L5 (64.4%), with disc herniation in 66.9% and lumbar spinal stenosis in 22.7%. Spondylolisthesis was present at L5/S1 in 6.1% and was associated with spinal stenosis in 18.9% of those cases. The study concludes that lumbar disc degenerative disease occurs frequently in advanced age and calls for research to reduce risk factors and improve quality of life.
A 1984 study of a private neurosurgical practice over five years reports that 64% of patients requiring disc surgery had satisfactory results and 12% were frank failures. Younger patients with single-level disc rupture had the best results. 18% of all patients required further surgery for recurrent disc problems, and the complication rate was 4%. The author states that compensation bias invalidates any critique of a therapy mode and creates a tremendous economic impact, and that improvement in surgical management is needed.
What is still missing are completed clinical trials of any biological or regenerative treatment that report patient outcomes, survival, or response rates. No drug is mentioned in any of these abstracts. The evidence base for novel treatments remains theoretical, and no trial design or patient stratification strategy has been validated. Funding for such trials and a clear definition of which patients might benefit are absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Advances in Orthopedics · 2012 · 161 citations · open access
Lumbar Degenerative Disc Disease: Current and Future Concepts of Diagnosis and Management
AbstractLow back pain as a result of degenerative disc disease imparts a large socioeconomic impact on the health care system. Traditional concepts for treatment of lumbar disc degeneration have aimed at symptomatic relief by limiting motion in the lumbar spine, but novel treatment strategies involving stem cells, growth factors, and gene therapy have the theoretical potential to prevent, slow, or even reverse disc degeneration. Understanding the pathophysiological basis of disc degeneration is essential for the development of treatment strategies that target the underlying mechanisms of disc degeneration rather than the downstream symptom of pain. Such strategies ideally aim to induce disc regeneration or to replace the degenerated disc. However, at present, treatment options for degenerative disc disease remain suboptimal, and development and outcomes of novel treatment options currently have to be considered unpredictable.
Asian Spine Journal · 2013 · 147 citations · open access
Lumbar Disc Degenerative Disease: Disc Degeneration Symptoms and Magnetic Resonance Image Findings
AbstractSTUDY DESIGN: Cross sectional and observational. PURPOSE: To evaluate the different aspects of lumbar disc degenerative disc disease and relate them with magnetic resonance image (MRI) findings and symptoms. OVERVIEW OF LITERATURE: Lumbar disc degenerative disease has now been proven as the most common cause of low back pain throughout the world. It may present as disc herniation, lumbar spinal stenosis, facet joint arthropathy or any combination. Presenting symptoms of lumbar disc degeneration are lower back pain and sciatica which may be aggravated by standing, walking, bending, straining and coughing. METHODS: This study was conducted from January 2012 to June 2012. Study was conducted on the diagnosed patients of lumbar disc degeneration. Diagnostic criteria were based upon abnormal findings in MRI. Patients with prior back surgery, spine fractures, sacroiliac arthritis, metabolic bone disease, spinal infection, rheumatoid arthritis, active malignancy, and pregnancy were excluded. RESULTS: During the targeted months, 163 patients of lumbar disc degeneration with mean age of 43.92±11.76 years, came into Neurosurgery department. Disc degeneration was most commonly present at the level of L4/L5 105 (64.4%).Commonest types of disc degeneration were disc herniation 109 (66.9%) and lumbar spinal stenosis 37 (22.7%). Spondylolisthesis was commonly present at L5/S1 10 (6.1%) and associated mostly with lumbar spinal stenosis 7 (18.9%). CONCLUSIONS: Results reported the frequent occurrence of lumbar disc degenerative disease in advance age. Research efforts should endeavor to reduce risk factors and improve the quality of life.
A Critique of the Surgical Management of Lumbar Disc Disease in a Private Neurosurgical Practice
AbstractThe magnitude of the lumbar disc problem is reviewed and a profile of medical and surgical therapeutic expectations is presented. A study of a 5-year epoch of a neurosurgical practice indicated that 64% of all patients requiring disc surgery had satisfactory results and 12% were frank failures. The younger patients with single level disc rupture had the best results, and 18% of all patients required further surgery for recurrent disc problems. The complication rate was 4%. The bias of compensation invalidates any critique of a therapy mode and creates a tremendous economic impact. The need for improvement in the surgical management of lumbar disc disease is established.
Saudi Journal for Health Sciences · 2015 · 13 citations · open access
Novel treatment strategies for intervertebral disc degeneration
AbstractIntervertebral disc degenerative (IVDD) is a common orthopaedic condition characterized by a series of cellular, biochemical, structural and functional changes that imparts a large socioeconomic impact on healthcare system. Progressive loss of normal extracellular matrix constituents, namely proteoglycans and water content, is thought to be a key contributor to IVDD. The ability to sustain or augment normal matrix composition may slow down or reverse disc degeneration. Traditional concepts for treatment of lumbar disc degeneration have aimed at symptomatic relief by limiting motion in the lumbar spine, but novel treatment strategies involving direct injection of active substance, stem cells, growth factors and gene therapy have been attracting more attention in respect to prevent, slow or even reverse disc degeneration. Understanding the pathophysiological basis of disc degeneration will lay the foundation for the emergence of exciting new regenerative or reparative biological treatments for this debilitating condition either by inducing disc regeneration or replacing the degenerated disc.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
